2024 DOJ Settlement

On May 21, 2024, Magellan Diagnostics, Inc. (Magellan), entered into an agreement with the U.S. Department of Justice (DOJ) that resolved the DOJ’s investigation of Magellan that began in 2018. The investigation primarily involved conduct by former Magellan employees that occurred between 2013 and 2017 concerning the use of venous blood samples with Magellan’s LeadCare® line of products.  The use of venous blood samples was discontinued in 2018, and the product-related issues involved in the investigation were fully remediated at that time.  As part of the resolution, Magellan will pay $42 million over time in accordance with the negotiated terms of the settlement.  Magellan also agreed to make certain information about the settlement available to the public on the Magellan website, and links to that information can be found below.  Finally, Magellan agreed to create and fund a Victim Compensation Fund (the VCF), and more information about the VCF, including a form for submitting claims, will be made available on this page in the future.